Product Description
a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15087818/)
Mechanisms of Action: PARP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rocket Pharmaceuticals
Company Location: NEW YORK NY 10118
Company CEO: Gaurav Shah
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Wound Infection
Phase 2: Other|ST Elevation Myocardial Infarction
Phase 1: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IPC-06-2004 | P1 |
Terminated |
Melanoma |
None |
2019-03-21 |
Treatments |
|
| 2005-000464-95 | P2 |
Terminated |
Unknown |
2007-08-17 |
2022-03-12 |
Treatments |
|
| IPC-05-2004 | P2 |
Terminated |
Other |
None |
2019-03-21 |
Treatments |
|
| IPC-15-2003 | P2 |
Completed |
ST Elevation Myocardial Infarction |
None |
2019-03-21 |
Treatments |
|
| 2006-7041-83/hah | P4 |
Not yet recruiting |
Wound Infection |
2017-02-07 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/08/2021 |
News Article |
Claritas Announces Formation of Nitric Oxide Scientific Advisory Board |